cp wire

CP Wire Articles

Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based... read more

Thu, 01/24/19 - 10:12 am
  • The research demonstrates that specific, human microbiome-derived bacteria assembled rationally into consortia can cooperatively enhance the responses to immune checkpoint inhibitors
  • ... read more
Thu, 01/24/19 - 12:19 am

Gossamer Bio announced terms for it's $230 Million IPO on 1/23/19. The company plans to offer 14.4 million shares at $16 per share. Insiders have expressed an interest in acquiring $100 million of... read more

Wed, 01/23/19 - 09:14 pm

Talee Bio, Inc. announced on 1/23/19 agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL... read more

Wed, 01/23/19 - 09:37 am

BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR... read more

Wed, 01/23/19 - 09:22 am

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has partnered and established a collaboration with the Ladak Laboratory at Western University,... read more

Tue, 01/22/19 - 10:53 am

According to this regulatory filing, Pappas has raised a new $85.7 million investment... read more

Thu, 01/17/19 - 09:35 am
  • Erleada is also approved in the US for the treatment of non-metastatic castration-resistant prostate cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson... read more

Wed, 01/16/19 - 09:52 am
  • Facility will officially open in 1Q 2019
  • Ph I/II study on KB103 interim results met primary and secondary endpoints

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS... read more

Tue, 01/15/19 - 09:51 am
  • The tafamidis meglumine form (20 mg capsule) has been granted Priority Review

  • Tafamidis was granted Orphan Drug Designation for ATTR-CM in both the EU and US in 2012

... read more

Mon, 01/14/19 - 10:09 am
Cresskill, NJ.  Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease today announced the appointment of John... read more
Thu, 01/10/19 - 03:22 pm

Numerate, Inc. announced on 1/7/19 a multi-target research collaboration with Lundbeck Pharmaceutical to identify clinical candidates for the treatment of disorders in the central nervous system,... read more

Mon, 01/7/19 - 10:05 am

Atlantic Therapeutics announced on 1/7/19 that it has closed €28 million in Series B funding to continue its rapid growth trajectory.
Having recently gained FDA clearance for its INNOVO® ... read more

Mon, 01/7/19 - 09:48 am

Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions announced on 1/4/19 the closing of a $... read more

Fri, 01/4/19 - 09:13 am

Ablative Solutions, Inc. announced on 1/3/19 the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar... read more

Thu, 01/3/19 - 09:50 am

Wave Life Sciences Ltd. (NASDAQ: WVE announced on 1/3/19 that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for... read more

Thu, 01/3/19 - 09:41 am

Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for MYO-102, a novel gene therapy candidate for alpha-... read more

Wed, 01/2/19 - 09:54 am

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed... read more

Wed, 01/2/19 - 09:46 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.